Published in J Clin Microbiol on December 12, 2007
Association of oncogenic and nononcogenic human papillomavirus with HIV incidence. J Acquir Immune Defic Syndr (2010) 1.54
Cigarette smoking is an independent risk factor for cervical intraepithelial neoplasia in young women: a longitudinal study. Eur J Cancer (2009) 1.01
Transplacental transmission of Human Papillomavirus. Virol J (2008) 0.99
Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women. J Infect Dis (2012) 0.94
Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review. J Adolesc Health (2012) 0.89
Maternal transmission of human papillomavirus in retinoblastoma: A possible route of transfer. Indian J Med Paediatr Oncol (2012) 0.78
Population-based human papillomavirus 16, 18, 6 and 11 DNA positivity and seropositivity in Chinese women. Int J Cancer (2012) 0.78
High Burden of Human Papillomavirus (HPV) Infection among Young Women in KwaZulu-Natal, South Africa. PLoS One (2016) 0.76
Viral infections associated with oral cancers and diseases in the context of HIV: a workshop report. Oral Dis (2016) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst (1995) 18.86
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
Classification of papillomaviruses. Virology (2004) 14.16
Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer (2003) 8.01
Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis (2005) 3.84
A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis (2005) 3.46
Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer (2006) 3.38
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis (2000) 3.36
The epidemiology of genital human papillomavirus infection. Vaccine (2006) 3.28
Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine (2006) 2.95
Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine (2006) 2.51
Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer (2004) 2.33
The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis (1996) 2.21
Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer (2001) 1.82
Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis (2003) 1.57
Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer (2003) 1.55
Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. Cancer Epidemiol Biomarkers Prev (2004) 1.54
HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study. BMC Cancer (2006) 1.54
High prevalence of HPV 16 in South African women with cancer of the cervix and cervical intraepithelial neoplasia. J Med Virol (2003) 1.12
A case-control study of risk factors for invasive cervical cancer among U.S. women exposed to oncogenic types of human papillomavirus. Cancer Epidemiol Biomarkers Prev (2004) 1.08
Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa). Cancer Causes Control (2003) 1.08
Cervical human papillomavirus (HPV) infection in South African women: implications for HPV screening and vaccine strategies. J Clin Microbiol (2007) 1.05
Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and-negative women. J Infect Dis (1996) 1.04
A study of serum immunoglobulin levels in elderly persons that provides new insights into B cell immunosenescence. Ann N Y Acad Sci (2006) 1.01
Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations. Int J Cancer (1996) 0.92
Seroprevalence of human papillomavirus type 16 in pregnant women. Obstet Gynecol (1999) 0.90
Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions. Int J Cancer (1998) 0.89
Characterization of IgA response among women with incident HPV 16 infection. Virology (2003) 0.89
Human papillomaviruses and cancer in Uganda. Eur J Cancer Prev (2004) 0.86
Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses. J Clin Microbiol (2003) 0.86
Age distribution of antibodies to human papillomavirus in children, women with cervical intraepithelial neoplasia and blood donors from South Africa. J Med Virol (1997) 0.85
The agreement between cervical abnormalities identified by cytology and detection of high-risk types of human papillomavirus. S Afr Med J (2006) 0.82
Serum immunoglobulin A response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis (2003) 0.78
A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. PLoS One (2010) 3.38
Prevalence and determinants of fertility intentions of HIV-infected women and men receiving antiretroviral therapy in South Africa. AIDS Patient Care STDS (2007) 3.19
Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS (2010) 2.83
Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis (2009) 2.66
Effect of HIV-1 infection on T-Cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med (2006) 2.40
Initiation of oral contraceptives using a quick start compared with a conventional start: a randomized controlled trial. Obstet Gynecol (2007) 2.38
Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans. Clin Infect Dis (2007) 2.23
Statin use and the risk of breast and prostate cancer. Epidemiology (2002) 2.15
Malignant salivary gland tumours: can fast neutron therapy results point the way to carbon ion therapy? Radiother Oncol (2013) 2.07
Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets. J Fam Plann Reprod Health Care (2011) 2.07
Change in optic nerve sheath diameter as a radiological marker of outcome from endoscopic third ventriculostomy in children. Childs Nerv Syst (2015) 2.04
Intimate partner violence: prevalence and risk factors for men in Cape Town, South Africa. Violence Vict (2006) 1.88
Validation of cervical cancer screening methods in HIV positive women from Johannesburg South Africa. PLoS One (2013) 1.83
Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: a cross-sectional study. BMC Infect Dis (2008) 1.82
The global cardiovascular diseases risk pattern in a peri-urban working-class community in South Africa. The Mamre study. Ethn Dis (2004) 1.73
Sexual violence against intimate partners in Cape Town: prevalence and risk factors reported by men. Bull World Health Organ (2004) 1.65
Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis (2009) 1.62
Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol (2008) 1.62
Introducer catheter for fiberoptic intubation does exist. Anesth Analg (2006) 1.56
HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study. BMC Cancer (2006) 1.54
Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. Cancer Causes Control (2009) 1.52
Genital human papillomavirus prevalence and human papillomavirus concordance in heterosexual couples are positively associated with human immunodeficiency virus coinfection. J Infect Dis (2009) 1.50
The Million Women Study: potential biases do not allow uncritical acceptance of the data. Climacteric (2004) 1.50
Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS (2010) 1.43
Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses. PLoS One (2009) 1.43
Missed opportunities to address reproductive health care needs among HIV-infected women in antiretroviral therapy programmes. Trop Med Int Health (2007) 1.41
The epidemiology of aplastic anemia in Thailand. Blood (2005) 1.38
Impact of mucosal inflammation on cervical human immunodeficiency virus (HIV-1)-specific CD8 T-cell responses in the female genital tract during chronic HIV infection. J Virol (2008) 1.31
Quick start: novel oral contraceptive initiation method. Contraception (2002) 1.30
Challenges to microbicide introduction in South Africa. Soc Sci Med (2006) 1.27
Reproductive decisions in HIV-infected individuals. Lancet (2005) 1.27
Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med (2012) 1.25
Human papillomavirus prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: a cross-sectional study. BMC Cancer (2009) 1.23
Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16. J Virol (2005) 1.22
Impact of human immunodeficiency virus 1 infection and inflammation on the composition and yield of cervical mononuclear cells in the female genital tract. Immunology (2009) 1.21
Knowledge and use of emergency contraception among women in the Western Cape province of South Africa: a cross-sectional study. BMC Womens Health (2007) 1.20
Diverse and high prevalence of human papillomavirus associated with a significant high rate of cervical dysplasia in human immunodeficiency virus-infected women in Johannesburg, South Africa. Acta Cytol (2009) 1.20
HIV-related stigma, isolation, discrimination, and serostatus disclosure: a global survey of 2035 HIV-infected adults. J Int Assoc Physicians AIDS Care (Chic) (2012) 1.18
Genomic diversity of human papillomavirus-16, 18, 31, and 35 isolates in a Mexican population and relationship to European, African, and Native American variants. Virology (2004) 1.16
High prevalence of HPV 16 in South African women with cancer of the cervix and cervical intraepithelial neoplasia. J Med Virol (2003) 1.12
Agreement between self- and clinician-collected specimen results for detection and typing of high-risk human papillomavirus in specimens from women in Gugulethu, South Africa. J Clin Microbiol (2007) 1.12
Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol (2003) 1.11
Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J Gen Virol (2006) 1.10
Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol (2003) 1.09
Ten years of democracy in South Africa: documenting transformation in reproductive health policy and status. Reprod Health Matters (2004) 1.08
Next-generation sequencing of cervical DNA detects human papillomavirus types not detected by commercial kits. Virol J (2012) 1.08
Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa). Cancer Causes Control (2003) 1.08
Two methods of self-sampling compared to clinician sampling to detect reproductive tract infections in Gugulethu, South Africa. Sex Transm Dis (2006) 1.07
The impact of the use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human papillomavirus in female sex workers. Virus Res (2006) 1.07
Evidence of unique genotypes of beak and feather disease virus in southern Africa. J Virol (2004) 1.06
Worldwide genomic diversity of the human papillomaviruses-53, 56, and 66, a group of high-risk HPVs unrelated to HPV-16 and HPV-18. Virology (2005) 1.06
Immune activation in the female genital tract during HIV infection predicts mucosal CD4 depletion and HIV shedding. J Infect Dis (2011) 1.06
Combined condom and contraceptive use among South African women. S Afr Med J (2006) 1.05
Cervical human papillomavirus (HPV) infection in South African women: implications for HPV screening and vaccine strategies. J Clin Microbiol (2007) 1.05
Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. AIDS Res Hum Retroviruses (2008) 1.05
A survey to assess knowledge and acceptability of the intrauterine device in the Family Planning Services in Cape Town, South Africa. J Fam Plann Reprod Health Care (2010) 1.04
More men than women make mucosal IgA antibodies to Human papillomavirus type 16 (HPV-16) and HPV-18: a study of oral HPV and oral HPV antibodies in a normal healthy population. BMC Infect Dis (2006) 1.03
The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infect Agent Cancer (2007) 1.03
Expression of HIV-1 antigens in plants as potential subunit vaccines. BMC Biotechnol (2008) 1.02
Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines. Vaccine (2005) 1.02
The use of nested polymerase chain reaction and restriction fragment length polymorphism for the detection and typing of mucosal human papillomaviruses in samples containing low copy numbers of viral DNA. J Virol Methods (2002) 1.01
Cervical and oral human papillomavirus types in HIV-1 positive and negative women with cervical disease in South Africa. J Med Virol (2008) 1.01
Survey of knowledge, attitudes and practices surrounding the intrauterine device in South Africa. Contraception (2010) 1.01
Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol Drug Saf (2002) 1.00
Differential immunogold localisation of sulphated and unsulphated keratan sulphate proteoglycans in normal and macular dystrophy cornea using sulphation motif-specific antibodies. Histochem Cell Biol (2006) 1.00
Papillomavirus subtypes are natural and old taxa: phylogeny of human papillomavirus types 44 and 55 and 68a and -b. J Virol (2005) 0.99
Influence of human immunodeficiency virus and CD4 count on the prevalence of human papillomavirus in heterosexual couples. J Gen Virol (2010) 0.99
Detection of human papillomavirus in urine and cervical swabs from patients with invasive cervical cancer. J Med Virol (2003) 0.98
Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference. Eur J Immunol (2007) 0.98
Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia. Immunology (2006) 0.98
The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antivir Ther (2011) 0.98
Transient expression of Human papillomavirus type 16 L1 protein in Nicotiana benthamiana using an infectious tobamovirus vector. Virus Res (2006) 0.97
Bleeding patterns after immediate vs. conventional oral contraceptive initiation: a randomized, controlled trial. Fertil Steril (2003) 0.97
Partner influence on early discontinuation of the pill in a predominantly Hispanic population. Perspect Sex Reprod Health (2004) 0.97